AI-powered drug discovery represents a revolutionary shift in how new medicines are identified, developed, and brought to market. It leverages the strengths of Artificial Intelligence, Machine Learning, and advanced computational techniques to accelerate, optimize, and de-risk the traditionally long, expensive, and high-failure-rate process of drug development.

The Problem with Traditional Drug Discovery:

The conventional drug discovery pipeline is notoriously inefficient:

• Time-Consuming: It typically takes 10-15 years for a new drug to go from concept to market.
• Massively Expensive: The average cost to develop a single new drug can exceed $2 billion.
• High Failure Rate: A staggering 90% or more of drug candidates fail during clinical trials, often due to lack of efficacy or unforeseen toxicity.
• Limited Scope: Traditional methods often rely on serendipity, trial-and-error, and human intuition, limiting the exploration of vast chemical and biological spaces.

How AI Transforms Drug Discovery:

AI addresses these challenges by bringing unprecedented speed, precision, and predictive power to every stage of the drug discovery and development pipeline:

1. Target Identification and Validation:

• Traditional: A lengthy and often hit-or-miss process of identifying specific genes, proteins, or pathways that play a crucial role in a disease.
• AI’s Role: AI algorithms analyze vast, complex biological datasets (genomic, proteomic, transcriptomic, clinical, real-world patient data) to:
  • Identify novel disease-associated targets (e.g., specific proteins or genes).
  • Predict the most promising targets with higher accuracy.
  • Uncover previously unknown disease mechanisms.
  • Example: Platforms like AtomNet use structure-based drug design to predict how different drug molecules will interact with a target. DeepMind’s AlphaFold has revolutionized protein structure prediction, providing invaluable insights into potential drug binding sites.

2. Hit Identification & Lead Discovery (Virtual Screening):

• Traditional: High-throughput screening (HTS) of millions of compounds in physical labs, which is costly and time-consuming.
• AI’s Role: AI excels at virtual screening, computationally sifting through vast chemical libraries (billions of compounds) to identify “hits” that are likely to bind to a specific drug target.
  • Predicts binding affinity and potential efficacy.
  • Reduces the number of compounds needing physical synthesis and testing.
  • Example: Generative AI models can even design new molecules from scratch with desired properties, rather than just screening existing ones.

3. Lead Optimization:

• Traditional: Iteratively modifying identified “lead” compounds to improve their potency, selectivity, and pharmacokinetic properties (absorption, distribution, metabolism, excretion – ADME).
• AI’s Role: AI models can:
  • Predict ADME/T (Absorption, Distribution, Metabolism, Excretion, Toxicity) properties of drug candidates, identifying potential safety issues early.
  • Optimize molecular structures to enhance desired characteristics (e.g., solubility, stability, bioavailability) and minimize side effects.
  • Guide medicinal chemists on how to modify a molecule for optimal performance.
  • Example: Schrödinger’s AI-driven platform uses predictive modeling to optimize molecular structures.

4. Drug Repurposing (Repositioning):

• Traditional: Often serendipitous discovery of new uses for existing, approved drugs.
• AI’s Role: AI analyzes vast datasets of clinical and molecular data to identify existing drugs that may have therapeutic potential for different diseases.
  • Connects molecular mechanisms of existing drugs to disease pathways they weren’t originally designed for.
  • Benefit: Significantly accelerates the development timeline and reduces costs, as safety profiles are already known.
  • Example: AI can uncover “useful articles in lower impact journals that no one has ever seen” that hint at new indications for existing drugs.

5. Preclinical Testing & Predictive Toxicology:

• Traditional: Animal testing and in vitro assays to assess safety and efficacy before human trials.
• AI’s Role: AI models can:
  • Predict the safety profile and potential toxicity of drug candidates by analyzing preclinical data, minimizing the risk of adverse events in humans.
  • Identify toxicological patterns (e.g., hepatotoxicity, cardiotoxicity) early, allowing for the elimination of unsafe candidates.
  • Reduce the need for extensive and costly animal testing.

6. Clinical Trial Optimization:

• Traditional: Slow patient recruitment, high dropout rates, and complex trial design leading to prolonged and expensive trials.
• AI’s Role: AI is revolutionizing clinical trials by:
  • Patient Recruitment: Analyzing electronic health records (EHRs) and other real-world data to identify suitable candidates more efficiently and precisely match patients to trials.
  • Trial Design: Optimizing trial protocols, predicting the most effective dosing and treatment regimens, and enabling adaptive trial designs based on interim results.
  • Monitoring & Analysis: Real-time monitoring of patient responses and early detection of adverse events, improving safety and efficacy.
  • Example: AI-driven platforms like Antidote match patients to trials using natural language processing (NLP).

Benefits of AI in Drug Discovery:

• Accelerated Timelines: Compressing years of research into months, significantly reducing the time from discovery to market.
• Reduced Costs: Lowering the immense financial burden by minimizing failed experiments, optimizing resource allocation, and shortening development cycles.
• Higher Success Rates: Increasing the likelihood of clinical success by more accurately predicting drug efficacy and toxicity early in the process. AI-discovered drugs in Phase 1 clinical trials have shown better success rates (80-90%) compared to traditionally discovered drugs (40-65%).
• Novel Discoveries: Uncovering new targets, mechanisms, and drug candidates that might be missed by traditional methods.
• Personalized Medicine: Enabling the development of highly targeted therapies based on individual patient genetic and biological profiles.
• Efficiency & Automation: Automating data analysis, simulation, and experimental design, freeing up human researchers for higher-level problem-solving.

Challenges of AI in Drug Discovery:

• Data Quality and Accessibility: AI models require vast amounts of high-quality, diverse, and well-curated data. Inconsistent, incomplete, or biased data can lead to inaccurate predictions.
• Explainability (Black Box Problem): Understanding why an AI model made a particular prediction can be challenging, which is crucial for regulatory approval and scientific validation.
• Regulatory Compliance: Regulatory bodies (like CDSCO in India, FDA in the US, EMA in Europe) are still developing frameworks for AI-driven drug development, leading to a “grey area.”
• Integration Complexity: Integrating AI tools with existing experimental workflows and data infrastructure can be complex.
• Talent Gap: A shortage of professionals skilled in both AI/ML and pharmaceutical sciences.
• Ethical Concerns: Issues around data privacy, consent, and potential algorithmic bias in patient selection or treatment recommendations.
• Validation: AI predictions still need rigorous experimental and clinical validation in “wet labs” and human trials.

AI-Powered Drug Discovery in India:

India, as the “pharmacy of the world” primarily for generics, has a significant opportunity to move into biopharmaceutical innovation through AI.

• Key Players & Initiatives:
  • Indian Council of Medical Research (ICMR): Actively collaborating with AI-powered platforms to accelerate drug development for diseases like Tuberculosis (TB), aiming for more accessible and affordable treatments.
  • Indian Institutes of Technology (IITs) & IISc: Conducting significant research in computational biology, AI for drug design, and bioinformatics.
  • Indian Pharma Companies (e.g., Biocon, Sun Pharma, Cipla): Increasingly exploring AI for drug screening, repurposing, and optimizing manufacturing processes. Cipla, for example, has reduced changeover duration by 22% with AI scheduling in manufacturing.
  • Startups: Several Indian startups are emerging in this space, such as Sravathi AI (Bangalore), which focuses on AI/ML for in silico chemistry, drug discovery, and material science, even collaborating with CSIR-CDRI for cancer treatments.
  • Government Support: Growing focus on AI infrastructure and policy support from bodies like MeitY to foster AI innovation in various sectors, including healthcare.
• Opportunity: AI can help India pivot from being a generic drug manufacturing hub to a leader in novel drug discovery, addressing both global and local disease burdens (e.g., neglected tropical diseases, TB, endemic cancers).

Conclusion:

AI-powered drug discovery is not just a technological advancement; it is a transformative force poised to revolutionize how we fight diseases. By dramatically reducing the time, cost, and risk associated with drug development, AI promises to bring more effective, safer, and potentially personalized medicines to patients faster. While challenges remain, the strategic adoption and ethical deployment of AI in drug discovery are critical for India to solidify its position as a global leader in pharmaceutical innovation and healthcare.

What is AI-Powered Drug Discovery?

AI-powered drug discovery refers to the revolutionary application of Artificial Intelligence (AI) and Machine Learning (ML) techniques to transform and accelerate the traditionally lengthy, expensive, and high-risk process of finding and developing new pharmaceutical drugs.

Instead of relying solely on traditional laboratory experiments and human intuition, AI uses advanced computational power to analyze vast, complex datasets, identify patterns, make predictions, and even generate novel molecular structures.

Here’s a breakdown of what it entails:

The Core Idea:

The traditional drug discovery pipeline is notorious for its inefficiency: it can take 10-15 years and billions of dollars to bring a single drug to market, with a very high failure rate (over 90% of candidates fail in clinical trials). AI aims to tackle these challenges by making the process faster, cheaper, and more successful.

How AI is Used Across the Drug Discovery Pipeline:

AI is integrated into virtually every stage of drug discovery and development:

1. Target Identification and Validation:
   • What it is: Identifying specific biological molecules (like proteins or genes) or pathways that are involved in a disease and could be “targeted” by a drug.
   • AI’s Role: AI analyzes massive datasets of genomic, proteomic, clinical, and scientific literature data to pinpoint novel disease targets, predict which ones are most promising, and uncover new insights into disease mechanisms. Tools like DeepMind’s AlphaFold, which predicts protein structures, are invaluable here.
2. Hit Identification and Lead Discovery (Virtual Screening):
   • What it is: Finding initial “hit” molecules that can bind to the identified drug target.
   • AI’s Role: Instead of physically testing millions of compounds (high-throughput screening), AI performs virtual screening. It computationally sifts through vast chemical libraries (billions of compounds) to predict which ones are most likely to bind effectively to the target protein. Generative AI can even design entirely new molecules with desired properties from scratch.
3. Lead Optimization:
   • What it is: Taking the initial “hit” compounds and modifying them to improve their potency, selectivity, and other critical drug-like properties (e.g., solubility, stability, how it’s absorbed and metabolized by the body).
   • AI’s Role: AI models predict the ADME/T (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties of drug candidates. This helps medicinal chemists optimize molecular structures to enhance desired characteristics while minimizing potential side effects and toxicity early on.
4. Drug Repurposing (Repositioning):
   • What it is: Finding new therapeutic uses for existing, already approved drugs.
   • AI’s Role: AI analyzes vast amounts of clinical and molecular data to identify existing drugs that might be effective against different diseases than their original indication. This significantly accelerates development, as the drugs’ safety profiles are already known.
5. Preclinical Testing & Predictive Toxicology:
   • What it is: Testing drugs in laboratory settings (in vitro) and in animals (in vivo) before human trials to assess safety and initial efficacy.
   • AI’s Role: AI models can predict the safety profile and potential toxicity of drug candidates with greater accuracy, reducing the need for extensive animal testing and minimizing the risk of adverse events in human clinical trials.
6. Clinical Trial Optimization:
   • What it is: The most expensive and time-consuming phase, involving testing drugs in human volunteers.
   • AI’s Role: AI helps by:
     • Patient Recruitment: Identifying suitable patients for clinical trials more efficiently by analyzing electronic health records (EHRs) and real-world data.
     • Trial Design: Optimizing trial protocols, predicting dosing regimens, and enabling adaptive trial designs that can be modified based on interim results.
     • Monitoring: Analyzing real-time data from trials to identify patient responses and adverse events more quickly.

Key Benefits of AI-Powered Drug Discovery:

• Speed: Drastically reduces the time taken for various stages, from target identification to lead optimization, potentially shortening the overall drug development timeline by years.
• Cost Reduction: Lowers the immense financial burden by minimizing failed experiments, optimizing resource allocation, and increasing the success rate.
• Increased Success Rates: Improves the likelihood of a drug candidate successfully navigating clinical trials by making more accurate predictions about efficacy and safety early on.
• Novel Discoveries: Enables the exploration of vast chemical and biological spaces, leading to the discovery of new targets, mechanisms, and drug candidates that traditional methods might miss.
• Personalized Medicine: Facilitates the development of highly targeted therapies tailored to individual patient genetic and biological profiles.

In essence, AI-powered drug discovery is about transforming a historically slow, expensive, and often serendipitous process into a more data-driven, efficient, and intelligent endeavor, with the ultimate goal of bringing more effective and safer medicines to patients faster.

Who is require AI-Powered Drug Discovery?

Courtesy: BBC StoryWorks

AI-powered drug discovery is not a niche requirement; it’s rapidly becoming a fundamental necessity for almost all stakeholders involved in bringing new medicines to patients. The “who” that requires it encompasses a wide range of entities in the pharmaceutical and biotech ecosystem:

1. Pharmaceutical Giants (Big Pharma):

• Why they need it: These companies face immense pressure to fill their drug pipelines, reduce R&D costs, accelerate time to market, and improve success rates. They have the resources (though often siloed data) and the sheer volume of research to benefit enormously from AI’s data processing capabilities.
• How they use it: To identify novel drug targets, screen vast chemical libraries, optimize lead compounds, predict toxicity, and enhance clinical trial design and patient recruitment. Many are forming partnerships with AI biotech startups or building in-house AI capabilities.
• Examples: Pfizer, Novartis, Sanofi, Janssen (J&J), Merck, Eli Lilly are all heavily investing in or partnering for AI-driven drug discovery.

2. Biotechnology (Biotech) Companies:

• Why they need it: Biotech companies, especially startups, are often more agile and innovation-driven. AI allows them to punch above their weight, rapidly explore novel therapeutic areas, and develop differentiated pipelines with fewer resources than traditional pharma. Their business model often relies on quick validation and proof-of-concept.
• How they use it: Many AI-first drug discovery companies (e.g., Insilico Medicine, Exscientia, BenevolentAI, Recursion, Atomwise) are biotech startups whose core offering is their AI platform. They use AI for de novo drug design, target validation, drug repurposing, and optimizing specific molecular properties.
• Examples in India: Startups like Sravathi AI, and others emerging in the Indian biotech ecosystem, are leveraging AI for in silico chemistry and drug discovery. Larger Indian biopharma companies like Biocon and Cipla are also exploring AI for various stages of their R&D and manufacturing processes.

3. Contract Research Organizations (CROs) & Contract Development and Manufacturing Organizations (CDMOs):

• Why they need it: CROs and CDMOs provide research, development, and manufacturing services to pharmaceutical and biotech companies. To remain competitive and offer cutting-edge services, they must integrate AI into their offerings.
• How they use it: For virtual screening, ADMET prediction, optimizing synthesis routes, and supporting clients with data-driven insights. Many are developing their own AI-assisted platforms.
• Examples in India: Companies like Aurigene (part of Dr. Reddy’s Laboratories) are developing AI-assisted drug discovery platforms to enhance their CRO services.

4. Academic & Research Institutions:

• Why they need it: Universities and research institutes are at the forefront of fundamental biological and chemical discoveries. AI provides powerful tools to analyze complex “omics” data (genomics, proteomics), predict protein structures (e.g., AlphaFold’s impact), and explore novel disease mechanisms.
• How they use it: For basic research, identifying new drug targets, understanding disease pathways, and developing novel computational methods for drug design. They also train the next generation of AI-savvy drug discoverers.
• Examples in India: IITs (e.g., IIT BHU with its NPTEL course on AI in Drug Discovery), IISc Bangalore, Amrita Vishwa Vidyapeetham, and institutions like the Translational Health Science and Technology Institute (THSTI) are actively engaged in AI for drug discovery research.

5. Investment Firms (Venture Capital, Private Equity):

• Why they need it: To identify promising startups and technologies in the highly competitive and risky pharmaceutical sector. AI-driven drug discovery companies often represent a high-potential investment due to their ability to de-risk and accelerate development.
• How they use it: To evaluate the scientific validity and market potential of AI platforms and drug candidates, assessing the technical capabilities and the intellectual property generated by AI.

6. Healthcare Systems & Hospitals (for Real-World Data & Personalized Medicine):

• Why they need it: As healthcare shifts towards personalized medicine, access to and analysis of real-world patient data becomes crucial. AI can help stratify patients for clinical trials and predict individual responses to treatments.
• How they use it: While not directly discovering drugs, they are critical partners in providing the vast datasets (electronic health records, genomic data) that train and validate AI models, and later, for implementing AI-guided personalized therapies.

7. Regulatory Bodies (e.g., FDA, EMA, CDSCO in India):

• Why they need it: While not users of AI for drug discovery, they require an understanding of AI-driven drug discovery to develop appropriate regulatory frameworks for evaluating and approving AI-generated or AI-optimized drugs. They need to ensure the safety, efficacy, and explainability of drugs developed with AI.

In essence, anyone seeking to accelerate, de-risk, optimize, or innovate in the process of bringing new medicines to patients fundamentally requires AI-powered drug discovery to remain competitive and impactful in the current and future biopharmaceutical landscape.

When is require AI-Powered Drug Discovery?

AI-powered drug discovery isn’t required “at a specific time” like a scheduled event. Instead, its requirement is continuous and increasingly urgent due to the inherent and ever-growing challenges of traditional drug development.

Here are the key “when” scenarios that necessitate AI-powered drug discovery:

1. When Facing the Immense Time and Cost of Traditional Drug Development:

• The “When”: Always. The conventional drug discovery process takes an average of 10-15 years and costs over $2 billion per approved drug, considering failures. These timelines and costs are unsustainable for rapidly emerging health crises or for developing treatments for rare diseases with small patient populations.
• Why AI is Required: AI drastically accelerates timelines (e.g., reducing early R&D cycles by up to 70%, potentially bringing the entire process down to 5 years from 10-15) and reduces costs by minimizing failed experiments, optimizing lead compounds, and streamlining various stages. Companies like Insilico Medicine have brought AI-discovered drugs into clinical trials in a fraction of the usual time and cost.

2. When Tackling High Failure Rates in Clinical Trials:

• The “When”: At every stage, particularly before entering preclinical and clinical trials. Historically, over 90% of drug candidates fail during clinical trials, often due to lack of efficacy or unforeseen toxicity.
• Why AI is Required: AI can predict drug efficacy and toxicity with greater accuracy earlier in the development process. By analyzing vast datasets, AI identifies compounds with a higher likelihood of success and flags potential safety issues before significant investment is made in human trials. This improves the success rate of candidates entering Phase I clinical trials, with some AI-discovered drugs showing 80-90% success rates compared to 40-65% for traditionally discovered drugs.

3. When Exploring the “Vast Chemical Space” and Novel Drug Targets:

• The “When”: When searching for truly innovative therapies, especially for complex diseases with unmet needs. The number of potential drug-like molecules is astronomically large (estimated at over 10^60), far beyond what can be physically synthesized and tested.
• Why AI is Required: AI, especially generative AI, can explore this chemical space efficiently. It can identify novel drug targets, predict interactions with unprecedented precision, and even design new molecules from scratch with desired properties, unlocking therapeutic avenues previously inaccessible.

4. When Rapid Response to Global Health Crises is Needed:

• The “When”: During pandemics (like COVID-19) or outbreaks of other rapidly spreading diseases.
• Why AI is Required: AI can accelerate drug repurposing (finding new uses for existing drugs) and quickly identify potential therapeutic candidates. During the COVID-19 pandemic, AI was instrumental in identifying existing drugs that could be repurposed for treatment or in rapidly screening compounds for antiviral activity.

5. When Striving for Personalized and Precision Medicine:

• The “When”: Increasingly, as healthcare moves towards tailoring treatments to individual patient profiles.
• Why AI is Required: AI can analyze an individual’s genomic data, electronic health records, and other real-world data to identify patient subgroups most likely to respond to a specific treatment. This enables the development of highly targeted therapies and optimizes clinical trial recruitment for specific patient populations.

6. When Data Volume and Complexity Become Overwhelming:

• The “When”: Continuously, as biological and chemical data grows exponentially. Genomic, proteomic, clinical, and real-world data are massive and complex.
• Why AI is Required: AI algorithms are essential to process, integrate, and derive insights from these vast, multi-modal datasets, identifying patterns and relationships that human researchers or traditional statistical methods would miss.

In essence, AI-powered drug discovery is required now and increasingly into the future because it offers the most viable path to overcome the inherent limitations of traditional methods, enabling the faster, more efficient, and more successful development of life-saving medicines. It’s about moving from a trial-and-error approach to a data-driven, intelligent, and predictive one.

where is require AI-Powered Drug Discovery?

AI-powered drug discovery is required wherever the traditional drug discovery process proves too slow, too expensive, or too limited to address pressing medical needs and scientific challenges.

This means it’s required in:

1. Research & Development (R&D) Labs:

• Pharmaceutical Companies (Big Pharma and Small Biotechs): This is the most direct application. AI is needed in their internal R&D departments and labs to accelerate every stage:
  • Target identification: To sift through vast genomic and proteomic data to find novel disease-related targets.
  • Compound screening: For virtual screening of billions of molecules, predicting binding affinities, and designing novel compounds in silico before any physical synthesis.
  • Lead optimization: To predict ADME/T (Absorption, Distribution, Metabolism, Excretion, Toxicity) properties and optimize molecular structures for better drug-likeness.
  • Drug repurposing: To identify new uses for existing drugs by analyzing their molecular profiles and biological effects.
• Contract Research Organizations (CROs): CROs that provide R&D services to pharma and biotech clients are increasingly integrating AI to offer more efficient and advanced services, staying competitive.
• Academic and Research Institutions: Universities, specialized research institutes (like IISc, IITs, THSTI in India), and government research labs require AI to conduct cutting-edge basic research, understand complex biological systems, and translate discoveries into potential therapies.

2. Clinical Trial Operations:

• Clinical Research Organizations (CROs): AI is used by CROs to optimize patient recruitment by analyzing real-world data and electronic health records (EHRs) to identify suitable candidates with specific genetic or clinical profiles.
• Pharmaceutical Companies: To design more efficient and adaptive clinical trials, predict trial outcomes, and monitor patient safety and efficacy in real-time.

3. Data-Intensive Environments:

• Bioinformatics and Computational Biology Centers: These centers, whether standalone or part of larger institutions, are where massive genomic, proteomic, transcriptomic, and clinical datasets are generated and analyzed. AI is the only way to extract meaningful insights from such complex data.
• “Omics” Research Facilities: Any facility dealing with genomics, proteomics, metabolomics, etc., requires AI to interpret the vast amounts of data produced by these high-throughput technologies to identify biomarkers or disease pathways.

4. Specialized AI/ML Drug Discovery Companies:

• AI-First Biotech Startups: Companies like Insilico Medicine, Exscientia, BenevolentAI, and Atomwise are fundamentally built on AI platforms. Their “where” is primarily their computational labs and partnerships with traditional pharma for experimental validation and clinical trials. In India, emerging startups like Molecule AI and Sravathi AI fit this description.

5. Regulatory Bodies (Indirectly):

• While not directly using AI for drug discovery, regulatory agencies (like CDSCO in India, FDA in the US, EMA in Europe) need to develop the expertise and infrastructure to evaluate AI-generated or AI-optimized drugs. They require an understanding of AI models, their data, and their predictions to ensure safety and efficacy before approving these novel medicines.

6. Anywhere New Drug Innovation is Prioritized:

• Diseases with Unmet Needs: For diseases that have historically been challenging to treat (e.g., Alzheimer’s, many cancers, rare diseases) or for which current treatments are inadequate, AI is required to explore new mechanisms and molecular approaches.
• Emerging Pathogens/Pandemics: As seen with COVID-19, AI is crucial for rapid drug repurposing and accelerated development of new antivirals or vaccines during global health crises.

In essence, AI-powered drug discovery is required wherever the ambition to innovate, accelerate, and de-risk drug development meets the challenge of vast data, complex biology, and urgent medical needs. It’s a global requirement, deeply impacting the future of healthcare.

How is require AI-Powered Drug Discovery?

AI-powered drug discovery isn’t something you “plug in” to instantly solve all problems. Rather, it is required as a strategic, systemic overhaul of the drug development process, driven by the inherent limitations of traditional methods and the escalating demands of modern medicine. The “how” it’s required can be understood by examining the fundamental ways it changes and improves the process:

1. By Enabling Unprecedented Data Analysis and Insight Generation:

• Traditional Limitation: The sheer volume and complexity of biological (genomic, proteomic), chemical, and clinical data generated today is overwhelming for human analysis. This often leads to missed insights, fragmented understanding, and inefficient decision-making.
• How AI is Required: AI/ML algorithms are uniquely capable of ingesting, integrating, and analyzing massive, heterogeneous datasets at scale and speed. They can identify subtle patterns, correlations, and causal relationships that are invisible to human researchers or traditional statistical methods.
  • Examples: AI can analyze millions of scientific papers to connect disparate research findings, correlate genetic markers with disease phenotypes, or predict protein-ligand binding affinities from vast molecular databases.
• Outcome: This enables more accurate target identification, faster hit-to-lead progression, and a deeper understanding of disease biology and drug mechanisms.

2. By Accelerating and De-risking Early-Stage Discovery:

• Traditional Limitation: The initial phases of drug discovery (target ID, hit finding, lead optimization) are notoriously time-consuming, expensive, and have very high failure rates. Many promising candidates fail due to unforeseen toxicity or lack of efficacy late in the process.
• How AI is Required:
  • Virtual Screening: AI can computationally screen billions of compounds in days, dramatically narrowing down the pool of candidates that need to be physically synthesized and tested. This saves immense time and resources.
  • Generative AI for De Novo Design: Instead of just screening existing molecules, AI can design entirely new molecules with optimized properties (e.g., binding affinity, solubility, specificity) from scratch, tailored to a specific target.
  • Predictive ADME/T: AI models predict how a drug will behave in the body (Absorption, Distribution, Metabolism, Excretion) and its potential Toxicity (ADME/T) early on. This helps filter out problematic compounds much sooner, reducing costly late-stage failures.
• Outcome: This streamlines the discovery funnel, leading to a higher quality of drug candidates entering preclinical and clinical development, thereby increasing overall success rates and significantly cutting costs.

3. By Optimizing and Streamlining Clinical Development:

• Traditional Limitation: Clinical trials are the longest, most expensive, and highest-risk stage of drug development, plagued by slow patient recruitment, high dropout rates, and complex logistical challenges.
• How AI is Required:
  • Patient Stratification and Recruitment: AI analyzes real-world data (EHRs, genomic data) to identify patients who are most likely to benefit from a particular drug or who fit specific trial criteria. This accelerates recruitment and improves trial efficiency.
  • Trial Design Optimization: AI can help design more efficient clinical trial protocols, predict optimal dosing regimens, and identify potential risks.
  • Real-time Monitoring: AI can continuously monitor patient data during trials to detect adverse events earlier or identify subpopulations that respond differently to treatment.
• Outcome: AI makes clinical trials faster, more efficient, and more likely to succeed, bringing life-saving treatments to patients sooner.

4. By Enabling Proactive Drug Repurposing:

• Traditional Limitation: Discovering new uses for existing, approved drugs is often serendipitous or requires extensive manual literature review.
• How AI is Required: AI algorithms can systematically analyze vast datasets of drug properties, disease pathways, and clinical outcomes to identify novel connections between existing drugs and new therapeutic indications.
• Outcome: This drastically reduces the time and cost for new drug development, as the safety profile of the repurposed drug is already well-established.

5. By Augmenting Human Expertise and Overcoming Talent Gaps:

• Traditional Limitation: The pharmaceutical industry faces a global shortage of highly specialized scientists (medicinal chemists, biologists, pharmacologists, toxicologists). These experts are often bogged down by data analysis and repetitive tasks.
• How AI is Required: AI acts as a powerful assistive tool, automating mundane tasks, providing rapid insights, and guiding experimental design. This frees up human scientists to focus on complex problem-solving, creative thinking, and interpreting results.
• Outcome: It supercharges the productivity of existing research teams and allows them to tackle more ambitious projects.

In summary, AI-powered drug discovery is required as an essential tool and a strategic imperative to overcome the inherent limitations of the existing drug development paradigm. It’s not just about doing things slightly better; it’s about fundamentally transforming the entire process to make it more intelligent, efficient, and ultimately, more successful in delivering critical medicines to humanity.

Case study on AI-Powered Drug Discovery?

Courtesy: Biotecnika

AI-powered drug discovery is no longer theoretical; it’s a rapidly evolving field with tangible successes. Here’s a prominent case study that highlights its impact:

---

Case Study: Insilico Medicine and the Discovery of INS018_055 for Idiopathic Pulmonary Fibrosis (IPF)

Company: Insilico Medicine, a clinical-stage generative AI-driven drug discovery company.

The Challenge in Traditional Drug Discovery (IPF Context):

Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, and often fatal lung disease characterized by the scarring of lung tissue. It has limited treatment options, and the development of new drugs has been notoriously difficult due to:

• Complex Biology: The exact mechanisms of IPF are not fully understood, making target identification challenging.
• High Attrition Rate: Many drug candidates fail in clinical trials due to lack of efficacy or unacceptable side effects.
• Long Development Timelines: The traditional process takes 10-15 years, during which patients with IPF often have a limited life expectancy.

Insilico Medicine’s AI-Driven Solution:

Insilico Medicine leveraged its proprietary Pharma.AI platform, which integrates various AI modules for:

1. Target Discovery (PandaOmics):
   • AI analyzed vast amounts of biological data (genomic, proteomic, clinical, and real-world data) related to fibrosis.
   • It identified and validated a novel, previously uncharacterized drug target implicated in IPF. This was crucial because traditional methods often struggle to find truly novel targets.
2. Molecule Generation (Chemistry42):
   • Once the novel target was identified, generative AI models (part of Chemistry42) were tasked with designing novel molecular structures that could bind effectively to this target.
   • The AI designed millions of potential compounds de novo (from scratch), considering drug-like properties, binding affinity, and potential toxicity. This process significantly reduced the need for iterative chemical synthesis and testing in the lab.
3. Predictive Modeling (ADMET and Toxicity):
   • AI models within the Pharma.AI platform predicted the Absorption, Distribution, Metabolism, Excretion, and Toxicity (ADMET) profiles of the generated molecules.
   • This allowed for the rapid filtering out of compounds that were likely to have poor pharmacokinetic properties or unacceptable side effects, well before physical synthesis or testing.
4. Automated Synthesis and Testing:
   • The most promising AI-designed molecules were then synthesized and tested in automated “wet labs,” feeding results back into the AI models for further refinement (Design-Make-Test-Analyze cycle).

Measurable Outcomes and Impact (INS018_055):

• Record Speed from Target to Preclinical Candidate: Insilico Medicine went from identifying the novel target to nominating a preclinical candidate (INS018_055) in just 18 months. This is a dramatic acceleration compared to the traditional timeline of 4-7 years for this stage.
• Reduced Cost: The cost incurred for this entire phase was a fraction of what traditional methods would typically require.
• First AI-Discovered, AI-Designed Drug to Enter Phase II Clinical Trials: INS018_055 became the first drug candidate for a novel target, with a novel molecular structure, entirely discovered and designed by AI, to enter human clinical trials (Phase I in early 2023, and subsequently Phase IIa).
• Positive Phase IIa Results: In early 2025, Insilico announced positive interim results from the Phase IIa trial (NCT05938920) for INS018_055. The drug showed a favorable safety and tolerability profile across all dose levels, and importantly, demonstrated a dose-dependent response in forced vital capacity (FVC), a key measure of lung function, after only 12 weeks of dosage. This suggests potential efficacy in treating IPF.

Significance of the Case Study:

The Insilico Medicine case with INS018_055 is a landmark achievement in AI-powered drug discovery for several reasons:

1. Full End-to-End AI Integration: It demonstrates the successful application of AI across the entire early drug discovery pipeline, from target identification to novel molecule generation and preclinical candidate nomination.
2. Validation in Humans: The progression to Phase II clinical trials and the promising initial results provide strong real-world validation of AI’s capability to deliver viable drug candidates.
3. Addressing Unmet Medical Needs: IPF is a severe disease, and a novel, effective treatment would significantly impact patients’ lives. AI’s ability to tackle such complex diseases is a major step forward.
4. Proof of Efficiency: It serves as concrete evidence that AI can dramatically reduce the time and cost associated with drug development, potentially reshaping the entire pharmaceutical industry.

This success story underscores that AI-powered drug discovery is moving beyond theoretical promise to deliver tangible results, paving the way for a new era of faster, more efficient, and potentially more successful drug development.

White paper on AI-Powered Drug Discovery?

White Paper: AI-Powered Drug Discovery – Revolutionizing the Pharmaceutical Landscape for a Healthier Future

---

Executive Summary

The pharmaceutical industry faces an unprecedented challenge: the escalating cost, time, and failure rates associated with bringing new drugs to market. Despite significant scientific advancements, the traditional drug discovery pipeline remains largely inefficient, leading to high drug prices and delays in patient access to life-saving therapies. Artificial Intelligence (AI) and Machine Learning (ML) are poised to revolutionize this landscape, offering transformative capabilities to accelerate every stage of drug development, from target identification to clinical trials. This white paper delves into the mechanics of AI-powered drug discovery, highlighting its critical applications, the measurable impact on timelines and costs, the evolving trends, and the strategic imperatives for global adoption, with a specific focus on India’s burgeoning role in this paradigm shift.

1. The Inefficient Status Quo of Drug Discovery

The conventional drug discovery and development process is a laborious journey, typically spanning 10 to 15 years and costing upwards of $2.6 billion per approved drug (accounting for failures). Key inefficiencies include:

• Vast Chemical Space: The sheer number of potential drug-like molecules is astronomically large (estimated at 10^60 to 10^100), making exhaustive traditional screening impossible.
• High Attrition Rates: Over 90% of drug candidates fail during clinical trials, often due to unforeseen toxicity or lack of efficacy, resulting in significant wasted investment.
• Data Overload: The exponential growth of biological, chemical, and clinical data overwhelms human capacity for analysis, leading to missed insights.
• Complex Disease Biology: Many diseases (e.g., Alzheimer’s, complex cancers, autoimmune disorders) have intricate underlying mechanisms that are poorly understood, hindering rational drug design.
• Manual & Iterative Processes: Traditional medicinal chemistry often involves laborious, trial-and-error synthesis and testing cycles.

These challenges underscore the urgent need for a paradigm shift that AI is uniquely positioned to deliver.

2. The Mechanics of AI-Powered Drug Discovery: A New Paradigm

AI-powered drug discovery leverages advanced computational algorithms and vast datasets to predict, simulate, and automate various aspects of drug development. It moves beyond brute-force experimentation to intelligent, data-driven design.

2.1 Core AI/ML Methodologies Employed:

• Machine Learning (ML): Supervised, unsupervised, and reinforcement learning algorithms are used for pattern recognition, prediction, and classification tasks.
• Deep Learning (DL): Neural networks (e.g., Convolutional Neural Networks, Recurrent Neural Networks, Graph Neural Networks, Transformers) excel at processing complex, high-dimensional data like molecular structures, protein sequences, and imaging data.
• Generative AI (GenAI): Models like Generative Adversarial Networks (GANs) and Variational Autoencoders (VAEs) can design novel molecular structures from scratch, optimizing for desired properties rather than just screening existing ones.
• Natural Language Processing (NLP): Used to extract insights from unstructured data in scientific literature, patents, and clinical notes.
• Reinforcement Learning: Can be used to guide the iterative process of molecule design and optimization, learning from simulated or experimental feedback.

2.2 Applications Across the Drug Development Pipeline:

• Target Identification & Validation (PandaOmics example):
  • How AI Helps: AI analyzes massive multi-omics datasets (genomics, proteomics, transcriptomics) alongside patient data and scientific literature to identify novel disease-associated genes, proteins, or pathways. It can predict the most promising targets and their relevance to disease, accelerating a phase that traditionally relies heavily on hypothesis generation and laborious experimental validation.
• Hit Identification & Lead Discovery (Virtual Screening & De Novo Design):
  • How AI Helps: AI algorithms rapidly screen virtual libraries containing billions of compounds to identify “hits” that are likely to bind to a specific drug target. Generative AI takes this further by creating new molecular entities with optimal properties (e.g., binding affinity, specificity, manufacturability), reducing the need for costly and time-consuming physical synthesis of less promising compounds.
• Lead Optimization (Chemistry42 example):
  • How AI Helps: AI models predict the ADME/T (Absorption, Distribution, Metabolism, Excretion, Toxicity) properties of drug candidates. This allows for early identification and modification of compounds with undesirable characteristics (e.g., poor solubility, high toxicity), significantly reducing late-stage failures and accelerating the optimization process.
• Drug Repurposing (Repositioning):
  • How AI Helps: By analyzing extensive molecular interaction data, clinical trial results, and disease pathways, AI can identify existing, approved drugs that may have therapeutic potential for different diseases. This drastically cuts down development time and cost, as the safety profile is already established.
• Preclinical Testing & Predictive Toxicology:
  • How AI Helps: AI models learn from historical data to predict the potential toxicity of compounds in humans, reducing the reliance on extensive animal testing and improving the selection of safer candidates for clinical trials.
• Clinical Trial Optimization:
  • How AI Helps: AI can identify suitable patient cohorts for clinical trials more efficiently by analyzing electronic health records (EHRs) and other real-world data, accelerating recruitment. It can also optimize trial designs, predict patient responses, and monitor for adverse events in real-time, making trials more efficient, cost-effective, and successful.

3. Measurable Impact: Accelerating Timelines and Reducing Costs

The “why” for AI’s requirement is evidenced by its quantifiable impact:

• Reduced R&D Costs: AI can cut research and development costs by up to 40%, primarily by reducing the number of failed experiments and streamlining lab work.
• Accelerated Timelines: AI-driven drug design has the potential to cut overall drug discovery timelines by 50% or more, potentially bringing a new drug to market in 5-7 years compared to the traditional 10-15 years. Companies like Insilico Medicine have demonstrated going from target identification to preclinical candidate in as little as 18 months, compared to the industry average of 42 months.
• Improved Success Rates: AI-designed drugs entering Phase 1 clinical trials have shown a higher probability of success (PoS) ranging from 80-90%, significantly outperforming the traditional range of 40-65%.
• Faster Identification of Candidates: AI can identify promising drug candidates 10 times faster than traditional methods, analyzing thousands of molecules in hours rather than months.

4. Trends and Challenges in AI-Powered Drug Discovery

4.1 Current Trends:

• Generative AI Proliferation: The rise of advanced generative models is enabling de novo drug design and accelerating lead optimization.
• Multimodal Data Integration: Combining various data types (genomics, proteomics, clinical imaging, text) for holistic insights.
• Cloud-Based AI Platforms: Increasing adoption of scalable cloud infrastructure for AI model training and deployment.
• Explainable AI (XAI): Growing focus on making AI decisions more transparent and interpretable to build trust and meet regulatory requirements.
• Automation of Lab Work: Integration of AI with robotics and automated synthesis platforms (“AI-driven labs”).
• Strategic Partnerships: Pharmaceutical giants are increasingly collaborating with AI-first biotech companies to leverage specialized AI expertise.

4.2 Challenges:

• Data Accessibility and Quality: AI models are only as good as the data they’re trained on. Proprietary datasets, inconsistent formatting, and data silos remain significant hurdles.
• “Black Box” Problem (Explainability): The complex nature of some AI algorithms makes it difficult to understand why a particular prediction was made, which can be an issue for regulatory approval.
• Regulatory Frameworks: Regulatory bodies are still evolving their guidelines for AI-generated or AI-optimized drugs, creating a “grey area.”
• Talent Gap: A shortage of professionals skilled in both AI/ML and life sciences/pharmaceuticals.
• Computational Resources: Training advanced AI models requires significant computational power and infrastructure.
• Adversarial AI: The emerging threat of AI being used by malicious actors to design new pathogens or bypass security systems.
• Overcoming Hype: Managing expectations and demonstrating consistent, repeatable success beyond initial proofs of concept.

5. India’s Position in AI-Powered Drug Discovery

India, often called the “pharmacy of the world” due to its robust generics manufacturing, is strategically positioned to become a significant player in novel drug discovery through AI.

• Key Strengths:
  • Abundant Talent Pool: A large base of skilled IT professionals, data scientists, and a growing number of bioinformatics experts.
  • Vast Data Resources: A large and diverse patient population providing rich datasets for AI training (with appropriate privacy safeguards).
  • Vibrant Startup Ecosystem: A burgeoning number of AI-first biotech startups focusing on drug discovery (e.g., Sravathi AI, Molecule AI).
  • Government Support: Initiatives like the National Digital Health Mission and increasing focus on AI research and development provide a supportive environment.
  • Pharma Industry Investment: Leading Indian pharmaceutical companies (e.g., Biocon, Cipla, Dr. Reddy’s) are actively exploring and investing in AI for R&D and manufacturing optimization.
• Opportunities for Growth:
  • Transitioning from a generics-focused industry to one leading in novel drug development.
  • Addressing unique local health challenges (e.g., neglected tropical diseases, drug-resistant infections).
  • Becoming a global hub for AI-driven drug discovery partnerships and services.

6. Strategic Recommendations for India’s AI-Powered Pharma Future

To fully realize the potential of AI in drug discovery, India must focus on:

• Data Infrastructure & Interoperability: Investing in secure, standardized, and interoperable health data platforms (e.g., National Health Stack) while ensuring stringent data privacy.
• Talent Development: Launching aggressive skilling and reskilling programs in AI/ML for life scientists and pharmaceutical professionals.
• Research & Innovation Hubs: Establishing dedicated AI-Pharma innovation centers to foster collaboration between academia, industry, and startups.
• Ethical AI Guidelines: Developing clear ethical and regulatory frameworks for AI in healthcare and drug discovery, including explainability and bias mitigation.
• Funding & Incentives: Providing targeted funding, grants, and tax incentives for AI-driven drug discovery R&D.
• Global Partnerships: Encouraging collaborations with leading global AI firms, academic institutions, and pharmaceutical companies to share expertise and accelerate progress.
• “Wet Lab” Automation: Investing in automated robotic labs to rapidly validate AI-generated hypotheses and molecules.

Conclusion

AI-powered drug discovery is no longer a futuristic concept; it is an indispensable tool driving the next generation of pharmaceutical innovation. By embracing AI strategically and comprehensively, India has the opportunity to not only accelerate the development of life-saving medicines for its own population but also solidify its position as a global leader in the cutting-edge of biopharmaceutical research and development. The integration of AI promises a future where drug discovery is faster, smarter, and ultimately, more successful in delivering health solutions to humanity.

Industrial Application of AI-Powered Drug Discovery?

AI-powered drug discovery is not just confined to the initial ideation phase; its industrial application spans across the entire drug development lifecycle, and even extends into manufacturing and supply chain, making the process faster, more efficient, and more reliable.

Here are the key industrial applications:

1. Early-Stage Drug Discovery & Preclinical Development (The R&D Core):

• Target Identification and Validation:
  • Application: Pharmaceutical companies and biotech firms use AI to analyze vast “omics” data (genomics, proteomics, metabolomics), patient data, and scientific literature.
  • Industrial Use: AI platforms (like Insilico Medicine’s PandaOmics) identify and prioritize novel disease targets that are most likely to respond to a drug, significantly reducing the “hit-or-miss” nature of traditional target discovery. This saves years and millions of dollars by focusing efforts on the most promising biological pathways.
• Hit Identification and Lead Discovery (Virtual Screening & Generative Design):
  • Application: Instead of physically screening millions of compounds, AI performs virtual screening, predicting how billions of compounds will interact with a specific target protein. Generative AI then designs novel molecules from scratch, optimizing for specific desired properties (e.g., binding affinity, specificity).
  • Industrial Use: Companies like Atomwise and Exscientia leverage AI to rapidly identify potential drug candidates (hits) and refine them into lead compounds with better characteristics. This dramatically cuts down the time and resources spent on synthesizing and testing less promising molecules in the lab.
• Lead Optimization and ADMET Prediction:
  • Application: AI models predict the ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties of drug candidates.
  • Industrial Use: Pharma companies integrate these AI tools to modify lead compounds to improve their drug-like qualities and reduce potential side effects. This crucial step helps filter out toxic or ineffective candidates early, preventing costly failures in later clinical stages.
• Drug Repurposing/Repositioning:
  • Application: AI analyzes existing drug data and disease mechanisms to identify new therapeutic uses for already approved drugs.
  • Industrial Use: This is a highly attractive industrial application as it significantly reduces development time and cost since the drugs’ safety profiles are already established. During the COVID-19 pandemic, AI was widely used by companies like BenevolentAI to identify existing drugs for potential treatment.

2. Clinical Development & Trials:

• Patient Stratification and Recruitment:
  • Application: AI analyzes real-world patient data (Electronic Health Records, genomic data, claims data) to identify specific patient subgroups that are most likely to respond to a particular drug or meet clinical trial criteria.
  • Industrial Use: Pharma companies and CROs (Contract Research Organizations) use AI to accelerate patient enrollment, increase trial efficiency, and ensure diversity in trial populations. This can cut recruitment timelines from months to weeks.
• Clinical Trial Design and Monitoring:
  • Application: AI helps optimize trial protocols, predict optimal dosing regimens, and identify early signals of efficacy or adverse events.
  • Industrial Use: Companies leverage AI to create more efficient and adaptive trial designs, potentially reducing the number of patients needed or shortening trial duration, leading to significant cost savings and faster market entry.
• Pharmacovigilance (Drug Safety Monitoring):
  • Application: AI analyzes vast amounts of unstructured data (e.g., social media, patient forums, clinician notes, adverse event reports).
  • Industrial Use: Pharma companies use AI to detect safety signals more quickly and comprehensively, ensuring faster response to potential drug side effects and enhancing regulatory compliance.

3. Pharmaceutical Manufacturing & Operations:

• Predictive Maintenance:
  • Application: AI analyzes real-time data from sensors on manufacturing equipment (e.g., bioreactors, tablet presses).
  • Industrial Use: Pharma manufacturers use AI to predict equipment failures before they occur, enabling proactive maintenance. This minimizes costly unplanned downtime, improves Overall Equipment Effectiveness (OEE), and ensures smooth, continuous production flows. AstraZeneca and J&J are known to use this.
• Process Optimization:
  • Application: AI models optimize complex manufacturing processes like chemical synthesis, fermentation, and formulation.
  • Industrial Use: Companies employ AI (often through reinforcement learning) to control manufacturing parameters in real-time to ensure consistent product quality, maximize yields, and reduce waste. Cipla in India has reportedly used AI to reduce changeover durations in manufacturing.
• Quality Control & Assurance (QA/QC):
  • Application: AI-powered computer vision systems and analytical tools monitor production lines and product quality.
  • Industrial Use: AI can identify anomalies, defects, or contamination in raw materials, in-process materials, or finished drug products (e.g., inspecting pills for imperfections, checking packaging integrity). This enhances product safety and reduces human error in manual quality checks.
• Supply Chain Optimization:
  • Application: AI analyzes historical sales, market trends, seasonality, and external factors.
  • Industrial Use: Pharma companies use AI for more accurate demand forecasting and inventory management, minimizing stockouts and overstocking. AI also optimizes logistics, route planning, and real-time shipment tracking, ensuring timely and cost-effective delivery while maintaining product integrity (e.g., temperature-controlled shipments).

4. Personalized Medicine:

• Application: AI integrates patient-specific data (genomic, proteomic, lifestyle, EHRs) to tailor drug treatments.
• Industrial Use: Pharmaceutical companies are using AI to develop precision therapies, especially in oncology and rare diseases, where treatments are designed for specific patient subgroups based on their unique biological profiles. This ensures that the right drug reaches the right patient, improving efficacy and reducing adverse effects.

In essence, AI’s industrial application in drug discovery and development is about creating “smart” pharmaceutical operations that are data-driven, predictive, automated, and ultimately, more successful and sustainable in addressing global health needs.

References

[edit]

1. ^ “The drug development process”. US Food and Drug Administration. 4 January 2018. Retrieved 18 December 2019.
2. ^ Jump up to:^a b c “The drug development process: Step 1: Discover”. US Food and Drug Administration. 4 January 2018. Archived from the original on 5 August 2019. Retrieved 18 December 2019.
3. ^ Jump up to:^a b Helleboid S, Haug C, Lamottke K, et al. The Identification of Naturally Occurring Neoruscogenin as a Bioavailable, Potent, and High-Affinity Agonist of the Nuclear Receptor RORα (NR1F1). Journal of Biomolecular Screening. 2014;19(3):399–406. https://doi.org/10.1177/1087057113497095.
4. ^ Herrmann, A., Roesner, M., Werner, T. et al. Potent inhibition of HIV replication in primary human cells by novel synthetic polyketides inspired by Aureothin. Sci Rep 10, 1326 (2020). https://doi.org/10.1038/s41598-020-57843-9.
5. ^ “The drug development process: Step 3: Clinical research”. US Food and Drug Administration. 4 January 2018. Retrieved 18 December 2019.
6. ^ Anson D, Ma J, He JQ (1 May 2009). “Identifying Cardiotoxic Compounds”. Genetic Engineering & Biotechnology News. TechNote. Vol. 29, no. 9. Mary Ann Liebert. pp. 34–35. ISSN 1935-472X. OCLC 77706455. Archived from the original on 21 September 2012. Retrieved 25 July 2009.
7. ^ Paul SM, Mytelka DS, Dunwiddie CT, Persinger CC, Munos BH, Lindborg SR, Schacht AL (March 2010). “How to improve R&D productivity: the pharmaceutical industry’s grand challenge”. Nature Reviews. Drug Discovery. 9 (3): 203–14. doi:10.1038/nrd3078. PMID 20168317. S2CID 1299234.
8. ^ Jump up to:^a b c d Current Model for Financing Drug Development: From Concept Through Approval. Institute of Medicine (US), Forum on Drug Discovery, Development, and Translation, National Academies Press, Washington (DC). 2009.
9. ^ Warren J (April 2011). “Drug discovery: lessons from evolution”. British Journal of Clinical Pharmacology. 71 (4): 497–503. doi:10.1111/j.1365-2125.2010.03854.x. PMC 3080636. PMID 21395642.
10. ^ Takenaka T (September 2001). “Classical vs reverse pharmacology in drug discovery”. BJU International. 88 (Suppl 2): 7–10, discussion 49–50. doi:10.1111/j.1464-410X.2001.00112.x. PMID 11589663.
11. ^ Lee JA, Uhlik MT, Moxham CM, Tomandl D, Sall DJ (May 2012). “Modern phenotypic drug discovery is a viable, neoclassic pharma strategy”. Journal of Medicinal Chemistry. 55 (10): 4527–38. doi:10.1021/jm201649s. PMID 22409666.
12. ^ Elion GB (1993). “The quest for a cure”. Annual Review of Pharmacology and Toxicology. 33: 1–23. doi:10.1146/annurev.pa.33.040193.000245. PMID 8494337.
13. ^ Elion GB. “The purine path to chemotherapy. Nobel Lecture 1988”.
14. ^ Black J. “Drugs from emasculated hormones: the principles of synoptic antagonism. Nobel Lecture 1988”. Retrieved 28 February 2014.
15. ^ Endo A. “The discovery of the statins and their development”. Retrieved 28 February 2014.
16. ^ Watts G (2012). “Obituary: Sir David Jack”. The Lancet. 379 (9811): 116. doi:10.1016/S0140-6736(12)60053-1. S2CID 54305535.
17. ^ Swinney DC, Anthony J (July 2011). “How were new medicines discovered?”. Nature Reviews. Drug Discovery. 10 (7): 507–19. doi:10.1038/nrd3480. PMID 21701501. S2CID 19171881.
18. ^ “Qubit Pharmaceuticals Accelerates Drug Discovery with Hybrid Quantum Computing”. HPC Wire. 30 November 2022.
19. ^ Rask-Andersen M, Almén MS, Schiöth HB (August 2011). “Trends in the exploitation of novel drug targets”. Nature Reviews. Drug Discovery. 10 (8): 579–90. doi:10.1038/nrd3478. PMID 21804595. S2CID 3328752.
20. ^ Jacobson KA (December 2015). “New paradigms in GPCR drug discovery”. Biochemical Pharmacology. 98 (4): 541–555. doi:10.1016/j.bcp.2015.08.085. PMC 4967540. PMID 26265138.
21. ^ Jump up to:^{a b c d e} Chen, Ya; Kirchmair, Johannes (6 September 2020). “Cheminformatics in natural product-based drug discovery”. Molecular Informatics. 39 (12): 2000171. doi:10.1002/minf.202000171. ISSN 1868-1743. PMC 7757247. PMID 32725781.
22. ^ Baker M (9 January 2017). “Deceptive curcumin offers cautionary tale for chemists”. Nature. 541 (7636): 144–145. Bibcode:2017Natur.541..144B. doi:10.1038/541144a. PMID 28079090.
23. ^ Dahlin JL, Walters MA (July 2014). “The essential roles of chemistry in high-throughput screening triage”. Future Medicinal Chemistry. 6 (11): 1265–90. doi:10.4155/fmc.14.60. PMC 4465542. PMID 25163000.
24. ^ Baell JB, Holloway GA (April 2010). “New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays”. Journal of Medicinal Chemistry. 53 (7): 2719–40. CiteSeerX 10.1.1.394.9155. doi:10.1021/jm901137j. PMID 20131845.
25. ^ Hopkins AL, Groom CR, Alex A (May 2004). “Ligand efficiency: a useful metric for lead selection”. Drug Discovery Today. 9 (10): 430–1. doi:10.1016/S1359-6446(04)03069-7. PMID 15109945.
26. ^ Ryckmans T, Edwards MP, Horne VA, Correia AM, Owen DR, Thompson LR, Tran I, Tutt MF, Young T (August 2009). “Rapid assessment of a novel series of selective CB(2) agonists using parallel synthesis protocols: A Lipophilic Efficiency (LipE) analysis”. Bioorganic & Medicinal Chemistry Letters. 19 (15): 4406–9. doi:10.1016/j.bmcl.2009.05.062. PMID 19500981.
27. ^ Leeson PD, Springthorpe B (November 2007). “The influence of drug-like concepts on decision-making in medicinal chemistry”. Nature Reviews. Drug Discovery. 6 (11): 881–90. doi:10.1038/nrd2445. PMID 17971784. S2CID 205476574.
28. ^ Lang, Stuart; Slater, Martin J. (9 May 2024). “Virtual Screening Strategies for Identifying Novel Chemotypes”. Journal of Medicinal Chemistry. 67 (9): 6897–6898. doi:10.1021/acs.jmedchem.4c00906. ISSN 0022-2623.
29. ^ Rester U (July 2008). “From virtuality to reality – Virtual screening in lead discovery and lead optimization: a medicinal chemistry perspective”. Current Opinion in Drug Discovery & Development. 11 (4): 559–68. PMID 18600572.
30. ^ Rollinger JM, Stuppner H, Langer T (2008). “Virtual screening for the discovery of bioactive natural products”. Natural Compounds as Drugs Volume I. Progress in Drug Research. Vol. 65. pp. 211, 213–49. doi:10.1007/978-3-7643-8117-2_6. ISBN 978-3-7643-8098-4. PMC 7124045. PMID 18084917.
31. ^ Barcellos GB, Pauli I, Caceres RA, Timmers LF, Dias R, de Azevedo WF (December 2008). “Molecular modeling as a tool for drug discovery”. Current Drug Targets. 9 (12): 1084–91. doi:10.2174/138945008786949388. PMID 19128219.
32. ^ Durrant JD, McCammon JA (October 2011). “Molecular dynamics simulations and drug discovery”. BMC Biology. 9: 71. doi:10.1186/1741-7007-9-71. PMC 3203851. PMID 22035460.
33. ^ Borhani DW, Shaw DE (January 2012). “The future of molecular dynamics simulations in drug discovery”. Journal of Computer-Aided Molecular Design. 26 (1): 15–26. Bibcode:2012JCAMD..26…15B. doi:10.1007/s10822-011-9517-y. PMC 3268975. PMID 22183577.
34. ^ Ciemny M, Kurcinski M, Kamel K, Kolinski A, Alam N, Schueler-Furman O, Kmiecik S (May 2018). “Protein-peptide docking: opportunities and challenges”. Drug Discovery Today. 23 (8): 1530–1537. doi:10.1016/j.drudis.2018.05.006. PMID 29733895.
35. ^ Erlanson DA, McDowell RS, O’Brien T (July 2004). “Fragment-based drug discovery”. Journal of Medicinal Chemistry. 47 (14): 3463–82. doi:10.1021/jm040031v. PMID 15214773.
36. ^ Folkers G, Jahnke W, Erlanson DA, Mannhold R, Kubinyi H (2006). Fragment-based Approaches in Drug Discovery (Methods and Principles in Medicinal Chemistry). Weinheim: Wiley-VCH. ISBN 978-3-527-31291-7.
37. ^ Erlanson DA (June 2011). “Introduction to fragment-based drug discovery”. Fragment-Based Drug Discovery and X-Ray Crystallography. Vol. 317. pp. 1–32. doi:10.1007/128_2011_180. ISBN 978-3-642-27539-5. PMID 21695633. {{cite book}}: |journal= ignored (help)
38. ^ Edward Z, Michael S (2008). Fragment-based drug discovery a practical approach. Wiley.
39. ^ Greaney MF, Bhat VT (2010). “Chapter 2: Protein-directed dynamic combinatorial chemistry”. In Miller BL (ed.). Dynamic combinatorial chemistry: in drug discovery, bioinorganic chemistry, and materials sciences. New Jersey: John Wiley & Sons. pp. 43–82.
40. ^ Huang R, Leung IK (July 2016). “Protein-directed dynamic combinatorial chemistry: a guide to protein ligand and inhibitor discovery”. Molecules. 21 (7): 910. doi:10.3390/molecules21070910. PMC 6273345. PMID 27438816.
41. ^ Mondal M, Hirsch AK (April 2015). “Dynamic combinatorial chemistry: a tool to facilitate the identification of inhibitors for protein targets”. Chemical Society Reviews. 44 (8): 2455–88. doi:10.1039/c4cs00493k. PMID 25706945.
42. ^ Herrmann A (March 2014). “Dynamic combinatorial/covalent chemistry: a tool to read, generate and modulate the bioactivity of compounds and compound mixtures”. Chemical Society Reviews. 43 (6): 1899–933. doi:10.1039/c3cs60336a. PMID 24296754.
43. ^ Hochgürtel M, Lehn JM (2006). “Chapter 16: Dynamic combinatorial diversity in drug discovery”. In Jahnke W, Erlanson DA (eds.). Fragment-based approaches in drug discovery. Weinheim: Wiley-VCH. pp. 341–364. ISBN 9783527312917.
44. ^ Caliandro R, Belviso DB, Aresta BM, de Candia M, Altomare CD (June 2013). “Protein crystallography and fragment-based drug design”. Future Medicinal Chemistry. 5 (10): 1121–40. doi:10.4155/fmc.13.84. PMID 23795969.
45. ^ Chilingaryan Z, Yin Z, Oakley AJ (October 2012). “Fragment-based screening by protein crystallography: successes and pitfalls”. International Journal of Molecular Sciences. 13 (10): 12857–79. doi:10.3390/ijms131012857. PMC 3497300. PMID 23202926.
46. ^ Valade A, Urban D, Beau JM (January–February 2007). “Two galactosyltransferases’ selection of different binders from the same uridine-based dynamic combinatorial library”. Journal of Combinatorial Chemistry. 9 (1): 1–4. doi:10.1021/cc060033w. PMID 17206823.
47. ^ Zheng W, Thorne N, McKew JC (November 2013). “Phenotypic screens as a renewed approach for drug discovery”. Drug Discovery Today. 18 (21–22): 1067–1073. doi:10.1016/j.drudis.2013.07.001. PMC 4531371. PMID 23850704.
48. ^ Swinney DC, Anthony J (June 2011). “How were new medicines discovered?”. Nature Reviews. Drug Discovery. 10 (7): 507–519. doi:10.1038/nrd3480. PMID 21701501. S2CID 19171881.
49. ^ Brown DG, Wobst HJ (March 2020). “Opportunities and Challenges in Phenotypic Screening for Neurodegenerative Disease Research”. Journal of Medicinal Chemistry. 63 (5): 1823–1840. doi:10.1021/acs.jmedchem.9b00797. PMID 31268707. S2CID 195798523.
50. ^ Moellering RE, Cravatt BF (January 2012). “How chemoproteomics can enable drug discovery and development”. Chemistry & Biology. 19 (1): 11–22. doi:10.1016/j.chembiol.2012.01.001. PMC 3312051. PMID 22284350.